Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Geert J.C.M. Kolvenbag"'
Autor:
Anthony Nash, Geert J.C.M. Kolvenbag
Publikováno v:
The Prostate. 39:47-53
BACKGROUND Androgen deprivation is often used for the treatment of patients with prostate cancer. Androgen deprivation can be achieved by surgical castration or medical castration, with or without using an antiandrogen. Each of these treatments may b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e501ff0022840fc84e54b0d4bba83a5c
https://doi.org/10.1002/(sici)1097-0045(19990401)39:1<47::aid-pros8>3.0.co
https://doi.org/10.1002/(sici)1097-0045(19990401)39:1<47::aid-pros8>3.0.co
Autor:
Michael F. Sarosdy, Eric A. Klein, Peter Venner, Gerald W. Chodak, Mark S. Soloway, A. Lynn Patterson, Julie Jones Schellenger, Norman L. Block, Geert J.C.M. Kolvenbag, Roohollah Sharifi, Paul F. Schellhammer, Nicholas J. Vogelzang
Publikováno v:
Urology. 52:82-88
Objectives. To perform exploratory analyses of data from a controlled trial that assessed the efficacy and tolerability of two antiandrogens, bicalutamide and flutamide, each combined with monthly depot preparations of leuprolide or goserelin, in pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76c7d00d9bac2875831f2c3377cb3925
https://doi.org/10.1016/s0090-4295(98)00145-9
https://doi.org/10.1016/s0090-4295(98)00145-9
Publikováno v:
The Prostate. 34:61-72
BACKGROUND Bicalutamide (Casodex®) is a new nonsteroidal antiandrogen developed for use in patients with prostate cancer. The efficacy and tolerability of bicalutamide as monotherapy and as combination therapy for patients with advanced prostate can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::235aa86ff9daadc6ecdb5eff9ef92a91
https://doi.org/10.1002/(sici)1097-0045(19980101)34:1<61::aid-pros8>3.0.co
https://doi.org/10.1002/(sici)1097-0045(19980101)34:1<61::aid-pros8>3.0.co
Autor:
Peter Venner, Michael F. Sarosdy, Paul F. Schellhammer, Roohollah Sharifi, Mark S. Soloway, A. Lynn Patterson, Nicholas J. Vogelzang, Julie Jones Schellenger, Geert J.C.M. Kolvenbag, Norman L. Block
Publikováno v:
Urology. 50:330-336
Objectives To compare the efficacy and tolerability of bicalutamide and flutamide, each combined with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with metastatic (Stage D2) prostate cancer. Methods This was a randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9b26dd07435898d83491fd3448fe7cd
https://doi.org/10.1016/s0090-4295(97)00279-3
https://doi.org/10.1016/s0090-4295(97)00279-3
Autor:
Zev Wajsman, Eric Klein, Peter N. Venner, Paul F. Schellhammer, A. Lynn Patterson, Peter T. Nieh, Yusong Chen, D. Rusby Seabaugh, Eric J. Small, Gabriel P. Haas, Geert J.C.M. Kolvenbag, Barry Furr
Publikováno v:
Journal of Urology. 157:1731-1735
Purpose: We determined whether decreases in prostate specific antigen (PSA) would occur after withdrawal of double-blinded antiandrogen therapy with flutamide or bicalutamide for clinical progression or increasing PSA concentration in patients receiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19d256fb919ed9ae56ce29c9b8db9544
https://doi.org/10.1016/s0022-5347(01)64846-8
https://doi.org/10.1016/s0022-5347(01)64846-8
Autor:
Geert J.C.M. Kolvenbag, Gerhard A. Dijkman, Wim P.J. Witjes, Frans M.J. Debruyne, Pilar Fernandez del Moral
Publikováno v:
Urology, 48, 6, pp. 894-900
Urology, 48, 894-900
Urology, 48, 894-900
Objectives. To compare the pharmacodynamics and tolerability of the new goserelin acetate 10.6mg depot with the 3.6-mg depot in patients with advanced prostate cancer during the first 3 months of therapy. Methods. One hundred sixty patients were rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd5e815e6bf0e418f0e384c372dbd2e
https://doi.org/10.1016/s0090-4295(96)00300-7
https://doi.org/10.1016/s0090-4295(96)00300-7
Publikováno v:
Anti-Cancer Drugs. 7:27-34
Maximum androgen blockade, a relatively recent development in the treatment of prostate cancer, combines medical or surgical castration with antiandrogen therapy. A large randomized study comparing the non-steroidal antiandrogen, bicalutamide, with f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2ef2d2802f9fb27435f8a91a44639ed
https://doi.org/10.1097/00001813-199601000-00002
https://doi.org/10.1097/00001813-199601000-00002
Autor:
Nicholas J. Vogelzang, A.L. Patterson, Geert J.C.M. Kolvenbag, J.A. Jones, Mark S. Soloway, Paul F. Schellhammer, Michael F. Sarosdy, Roohollah Sharifi, P.M. Venner
Publikováno v:
European Urology. 29:105-109
Between January 1992 and September 1993, 813 patients with stage D2 prostate cancer were enrolled in a multicentre, double-blind (for antiandrogen therapy) trial and randomised to antiandrogen therapy with Casodex (bicalutamide, 50 mg once daily) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05ce8ac631d68438229bff4344dd9fb9
https://doi.org/10.1159/000473848
https://doi.org/10.1159/000473848
Publikováno v:
Urology. 47:70-79
To evaluate bicalutamide as a therapy in nearly 3000 patients with advanced prostate cancer and to determine the dose-ranging, pharmacodynamic, and pharmacokinetic properties of bicalutamide. To evaluate bicalutamide as a monotherapy or in combinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f41f796d07332e6c7f4d14d449c6dcca
https://doi.org/10.1016/s0090-4295(96)80012-4
https://doi.org/10.1016/s0090-4295(96)80012-4
Autor:
Nicholas Vogelzang, Norman Block, Julie Jones, Roohollah Sharifi, Michael Sarosdy, Peter Venner, A. Lynn Patterson, Mark Soloway, Paul F. Schellhammer, Geert J.C.M. Kolvenbag
Publikováno v:
Urology. 45:745-752
Objectives To compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::016be8be64412b05433ffd56ca35b0a4
https://doi.org/10.1016/s0090-4295(99)80077-6
https://doi.org/10.1016/s0090-4295(99)80077-6